PURPOSE: To determine whether the method or extent of construction of the high-dose clinical target volume (CTV) and high-dose planning target volume (PTV) in intensity-modulated radiation therapy (IMRT) for head-and-neck cancer are associated with an increased risk of locoregional failure. MATERIALS AND METHODS: Patients with nasopharyngeal, oropharyngeal, oral cavity, hypopharyngeal, or laryngeal squamous cell carcinomas treated definitively with IMRT were included. All patients without local relapse had a minimum follow-up of 12 months. Median follow-up for all patients was 24 months. Treatment plans of 85 available patients were reviewed, and the gross tumor volume (GTV) to PTV expansion method was estimated. RESULTS: The GTVs were expanded volumetrically in 71 of 85 patients, by a median of 15 mm (range, 4-25 mm). An anatomic component to the expansion of GTV was used in 14 of 85 patients. Eighteen patients failed locoregionally, for an actuarial locoregional control rate of 77.2% at 2 years. There was no significant difference in locoregional control between patients with GTVs expanded volumetrically vs. those with a component of anatomic expansion. In patients with GTVs expanded volumetrically, no increase in risk of local failure was seen in patients with a total GTV expansion of < or =15 mm. CONCLUSION: In this retrospective study, there was not an increased risk of local failure using smaller margins or expanding GTVs volumetrically when treating head-and-neck cancer patients definitively with IMRT.
PURPOSE: To determine whether the method or extent of construction of the high-dose clinical target volume (CTV) and high-dose planning target volume (PTV) in intensity-modulated radiation therapy (IMRT) for head-and-neck cancer are associated with an increased risk of locoregional failure. MATERIALS AND METHODS:Patients with nasopharyngeal, oropharyngeal, oral cavity, hypopharyngeal, or laryngeal squamous cell carcinomas treated definitively with IMRT were included. All patients without local relapse had a minimum follow-up of 12 months. Median follow-up for all patients was 24 months. Treatment plans of 85 available patients were reviewed, and the gross tumor volume (GTV) to PTV expansion method was estimated. RESULTS: The GTVs were expanded volumetrically in 71 of 85 patients, by a median of 15 mm (range, 4-25 mm). An anatomic component to the expansion of GTV was used in 14 of 85 patients. Eighteen patients failed locoregionally, for an actuarial locoregional control rate of 77.2% at 2 years. There was no significant difference in locoregional control between patients with GTVs expanded volumetrically vs. those with a component of anatomic expansion. In patients with GTVs expanded volumetrically, no increase in risk of local failure was seen in patients with a total GTV expansion of < or =15 mm. CONCLUSION: In this retrospective study, there was not an increased risk of local failure using smaller margins or expanding GTVs volumetrically when treating head-and-neck cancerpatients definitively with IMRT.
Authors: Mischa de Ridder; Pieter D de Veij Mestdagh; Joris B W Elbers; Arash Navran; Charlotte L Zuur; Ludi E Smeele; Abrahim Al-Mamgani Journal: Eur Arch Otorhinolaryngol Date: 2019-10-10 Impact factor: 2.503
Authors: Adam R Burr; Paul M Harari; Alyx M Haasl; Aaron M Wieland; Justine Y Bruce; Randall J Kimple; Gregory K Hartig; Timothy M McCulloch; Matthew E Witek Journal: Head Neck Date: 2020-02-14 Impact factor: 3.147
Authors: Adam R Burr; Paul M Harari; Huaising C Ko; Justine Y Bruce; Randall J Kimple; Matthew E Witek Journal: Oral Oncol Date: 2019-03-22 Impact factor: 5.337
Authors: M de Ridder; Z A R Gouw; J J Sonke; A Navran; B Jasperse; J Heukelom; M E T Tesselaar; W M C Klop; M W M van den Brekel; Abrahim Al-Mamgani Journal: Eur Arch Otorhinolaryngol Date: 2016-12-09 Impact factor: 2.503
Authors: Imran Petkar; Keith Rooney; Justin W G Roe; Joanne M Patterson; David Bernstein; Justine M Tyler; Marie A Emson; James P Morden; Kathrin Mertens; Elizabeth Miles; Matthew Beasley; Tom Roques; Shreerang A Bhide; Kate L Newbold; Kevin J Harrington; Emma Hall; Christopher M Nutting Journal: BMC Cancer Date: 2016-10-06 Impact factor: 4.430
Authors: Olgun Elicin; Dario Terribilini; Mohamed Shelan; Werner Volken; Etienne Mathier; Alan Dal Pra; Daniel M Aebersold; Michael K Fix; Peter Manser Journal: Radiat Oncol Date: 2017-06-20 Impact factor: 3.481
Authors: Lara Bußmann; Simon Laban; Claus Wittekindt; Carmen Stromberger; Silke Tribius; Nikolaus Möckelmann; Arne Böttcher; Christian Stephan Betz; Jens Peter Klussmann; Volker Budach; Adrian Muenscher; Chia-Jung Busch Journal: BMC Cancer Date: 2020-07-29 Impact factor: 4.430